Current studentsExisting staffContact us
 

Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy

Simple item page
dc.contributor.authorOlver, I.
dc.contributor.authorGrimison, P.
dc.contributor.authorChatfield, M.
dc.contributor.authorStockler, M.
dc.contributor.authorToner, G.
dc.contributor.authorGebski, V.
dc.contributor.authorHarrup, R.
dc.contributor.authorUnderhill, C.
dc.contributor.authorKichenadasse, G.
dc.contributor.authorSinghal, N.
dc.contributor.authorDavis, I.
dc.contributor.authorBoland, A.
dc.contributor.authorMcDonald, A.
dc.contributor.authorThomson, D.
dc.date.issued2013
dc.descriptionLink to a related website: http://minerva-access.unimelb.edu.au/bitstream/11343/217907/1/Results%20of%20a%207_day%20aprepitant%20schedule%20for%20the%20prevention%20of%20nausea%20and%20vomiting%20....pdf, Open Access via Unpaywall
dc.description.abstractPURPOSE: The purpose of this study was to determine the efficacy of adding a 7-day aprepitant schedule to a 5HT3 receptor antagonist and dexamethasone for patients with germ cell tumors receiving first-line 5-day cisplatin-based chemotherapy. METHODS: In a single-arm, open-label, multi-center, phase 2 trial, chemo-naive patients received aprepitant 125 mg PO (per oral) on day 1 and 80 mg PO on days 2 to 7, a 5HT3 receptor antagonist on days 1 to 5, and dexamethasone 8 mg on days 1 to 8. The primary endpoint was no emesis (vomiting or dry retching) during days 1 to 7 of cycle 1. RESULTS: Fifty patients were recruited. For cycle 1, proportions reporting no emesis on day 1, no emesis on days 1 to 7, no nausea on day 1, and no nausea on days 1 to 7 were 96, 82, 71, and 27%, respectively. The efficacy was maintained in all cycles with over 80% of patients reporting no emesis on any given day of any given cycle. Emesis was more common on days 4 to 7 (68% episodes) than on days 1 to 3 (32% episodes). Over any 24-h period, 49% of patients with emesis reported no more than two episodes, and 62% of patients with nausea reported intensity as 3 or less on a scale from 0 to 10. There were no unexpected or serious adverse events reported. CONCLUSION: Adding 7 days of aprepitant to a 5HT3 receptor antagonist and dexamethasone effectively controlled acute and delayed emesis with 5-day cisplatin regimens. Days of nausea were more common than days of vomiting.
dc.description.statementofresponsibilityI. N. Olver, P. Grimison, M. Chatfield, M. R. Stockler, G. C. Toner, V. Gebski, R. Harrup, C. Underhill, G. Kichenadasse, N. Singhal, I. D. Davis, A. Boland, A. McDonald, D. Thomson, for the Australian and New Zealand Urogenital and Prostate Cancer Trials Group
dc.identifier.citationSupportive Care in Cancer, 2013; 21(6):1561-1568
dc.identifier.doi10.1007/s00520-012-1696-0
dc.identifier.issn0941-4355
dc.identifier.issn1433-7339
dc.identifier.orcidOlver, I. [0000-0001-5478-1576]
dc.identifier.urihttp://hdl.handle.net/2440/93411
dc.language.isoen
dc.publisherSpringer Verlag
dc.relation.grantNHMRC
dc.rights© Springer-Verlag Berlin Heidelberg 2012
dc.source.urihttps://doi.org/10.1007/s00520-012-1696-0
dc.subjectAprepitant
dc.subjectDexamethasone
dc.subject5Hydroxytryptamine3 receptor antagonist
dc.subject5-day cisplatin
dc.subjectAntiemetic
dc.subjectGerm cell tumors
dc.titleResults of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications